What Lutéran Treats: Main Uses and Benefits

The medication is utilized in clinical settings involving acute or unstable symptom patterns. Lutéran is commonly used to address conditions characterized by periods of heightened symptoms, including excessive menstrual bleeding (menorrhagia), dysfunctional uterine hemorrhages, endometriosis, and severe mastopathy (breast pain or tension).

The medication may be part of symptomatic management for these conditions, providing support that helps ease the overall symptom burden. It is often applied during phases when symptoms become more noticeable, offering relief that may help patients manage difficult episodes more steadily. This application is also relevant for managing physical manifestations that are difficult to tolerate, such as pronounced androgen-dependent symptoms (e.g., severe acne or hirsutism) resulting from systemic imbalance.

---

Quick Fact: Support for Chronic Gynecological Symptoms

Lutéran is applied in scenarios where additional management of discomfort is required for conditions involving episodic or fluctuating manifestations. This contributes to easing the overall symptom load and helps maintain stability during periods when symptoms are more noticeable.

Regulatory References

1. French National Medicines Safety Agency (ANSM) dossier on Lutéran

The eligibility for using high-dose Lutéran (Chlormadinone acetate, CMA) is strictly defined by regulatory authorities and centers on specific medical conditions and treatment duration.

Contraindicated Populations

The medicine is absolutely contraindicated (must not be used) for certain groups, as formally specified in official labeling:

• Patients with a meningioma or a history of this tumor, regardless of dose [EMA].
• Known or suspected pregnancy due to the risk of fetal harm.
• Patients with active liver disease (e.g., severe decompensated cirrhosis or liver tumors).
• Patients with undiagnosed abnormal uterine bleeding.
• Individuals at high risk for arterial or venous thromboembolic diseases.

Use Restrictions and Eligibility

Classification	Population/Condition	Restriction Statement
Restricted Use	High-Dose Treatment (5–10 mg)	Must be used at the lowest effective dose and for the shortest duration possible [EMA].
Not Recommended	Lactation/Breastfeeding	Progestins can pass into breast milk; use is generally advised against.
Not Established	Pediatric/Geriatric Use	Safety and efficacy are not extensively documented for these age groups in this context.

Eligibility is primarily established for adult women of childbearing age for specific gynecological disorders, provided they do not possess any of the absolute contraindications.

Interactions with other medicines and products

The official documentation for Lutéran (Chlormadinone acetate, CMA) details specific pharmacokinetic interactions arising from alterations to its metabolic clearance, primarily via the Cytochrome P450 3A4 (CYP3A4) enzyme system.

---

Pharmacokinetic Exposure Changes

Co-administration with substances that induce the CYP3A4 enzyme system is officially documented to decrease the plasma concentration and systemic exposure of CMA. Medicines in this category include potent Antiepileptics (e.g., Carbamazepine, Phenytoin) and strong Antibiotics (e.g., Rifampicin). Conversely, medicines that inhibit the CYP3A4 system, such as certain Azole Antifungals (e.g., Ketoconazole) and Macrolide Antibiotics (e.g., Clarithromycin), are documented to increase the plasma concentration of CMA. The herbal product St. John’s Wort (Hypericum perforatum) is also documented as a strong enzyme inducer, leading to reduced CMA exposure.

---

Interaction-Related Restrictions

The regulatory profile establishes a mandatory restriction tied to a patient’s health history. The use of high-dose Chlormadinone acetate (5 to 10 mg) is considered a contraindication in patients who have a pre-existing or past diagnosis of meningioma. This mandatory exclusion is stipulated by health authorities and is linked to the patient’s disease state. No timing-based separation rules for administration are documented in the official labeling.

The action of Lutéran (Chlormadinone acetate, CMA) involves the modulation of key hormonal and enzyme-mediated signaling pathways, resulting in defined physiological consequences.

Central Hormonal Feedback and HPO Modulation

CMA acts as an agonist on the Progesterone Receptor (PR), triggering a negative feedback signal in the hypothalamus and pituitary gland. This mechanism leads to the functional modulation of the Hypothalamic-Pituitary-Ovarian (HPO) axis, thereby reducing the systemic output of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH). This sequence results in the inhibition of intrinsic ovarian activity.

Dual-Targeted Antiandrogenism

Lutéran exhibits a dual mechanism to counteract the effects of androgens. It acts as a competitive antagonist on the Androgen Receptor (AR), blocking the signaling effects of hormones like testosterone. Concurrently, it functions as an inhibitor of the enzyme 5-alpha reductase (5α-reductase), reducing the local conversion of testosterone into the biologically more active dihydrotestosterone (DHT).

Local Tissue Stabilization and Enzyme Suppression

Locally, PR activation induces specific decidual transformation and atrophy of the uterine lining (endometrium), and increases cervical mucus viscosity. Furthermore, CMA reduces the local production of inflammatory mediators by suppressing Cyclooxygenase-2 (COX-2) expression within the endometrium.

How to Use Lutéran (Chlormadinone Acetate) — Administration Guidelines

Lutéran (chlormadinone acetate) is a prescription medication with specific parameters governing its route, dosage, frequency, and duration of administration. This information applies to the oral tablet form, which is the approved route for this product.

---

Dosing and Regimen

Usage is reserved for the adult population.

Dosing Entity	Instruction
Administration Route	Oral administration (tablet form)
Standard Daily Dose	Typically 10 mg per day, although the prescribed daily dose may range from 4 mg up to 10 mg.
Dosing Frequency	The total daily dose is taken either once daily or divided into two doses.
Intake Condition	The tablet should be taken with a liquid, such as water.

---

Administration Patterns and Timing

Administration follows two primary patterns, depending on the indication:

• Cyclic Administration: For many cycle-related disorders, the medication is administered for 10 consecutive days per menstrual cycle. This usually corresponds to taking the dose from Day 16 to Day 25 of the cycle, inclusive of both days.
• Continuous Administration: For conditions like endometriosis, the standard 10 mg daily dose may be administered on a continuous basis without scheduled interruption.

Missed Dose Management: If one tablet is missed, the forgotten dose should be disregarded and the treatment course continued by taking the next tablet at the regularly scheduled time. It is recommended to avoid doubling the dose. Missing multiple tablets may result in the scheduled cycle being interrupted, potentially leading to irregular bleeding.

Research Evidence / Overview of Studies for Lutéran (Chlormadinone Acetate)

This section provides a patient-friendly overview of the official research structure and findings regarding Lutéran (chlormadinone acetate), drawing only on authoritative regulatory and scientific sources. Research provides context but not individual predictions.

---

Evidence for Cycle-Related Issues: Menorrhagia and Dysmenorrhea

The active ingredient in Lutéran was studied in research exploring conditions characterized by acute or disruptive episodes, such as excessive menstrual bleeding (menorrhagia) and severe menstrual pain (dysmenorrhea). Studies exploring menorrhagia included observational cohorts and clinical trials relevant in trials assessing short-term or episodic symptom patterns. The main outcomes monitored by researchers included the objective and subjective measurement of menstrual blood loss and the tracking of bleeding days. Findings describe patterns observed in the studies; research highlights changes measured during the study period related to blood loss and the stability of bleeding patterns. However, evidence is limited in the form of large-scale, placebo-controlled randomized controlled trials (RCTs) for single-agent chlormadinone acetate for this indication. Long-term effects are not fully established, as follow-up durations were often limited to 3 to 12 cycles.

For dysmenorrhea, research explored outcomes related to physical discomfort. Data describe patterns related to changes in patient-reported pain scores and in the reliance on analgesics. A key limitation is that much of the available evidence is derived from studies where the active ingredient was associated with use in combination with estrogen, which was observed in some studies to make the specific contribution of single-agent Lutéran difficult to isolate.

---

Evidence for Endometriosis and Endometrial Conditions

Research also was evaluated in women diagnosed with endometriosis, a condition marked by functional limitations and periods of heightened symptoms. The studies explored measured outcomes related to physical discomfort, such as changes in pelvic pain scores, and tracked the frequency of induced amenorrhea (the absence of menstruation).

Research also was studied for a specialized purpose: a fertility-sparing approach for women with atypical endometrial hyperplasia or early endometrial carcinoma. Evidence for this is largely derived from prospective observational studies and non-randomized fertility-sparing registries, due to the specific and specialized nature of this population. These studies monitored the rate of Complete Remission (CR) of the abnormal tissue and subsequent disease recurrence. Sample sizes were modest in these specialized studies, and comparative evidence is limited against other treatments.

---

Evidence for Androgen-Dependent Symptoms

Lutéran was observed in studies used in research exploring how symptoms change over time associated with excess androgens. The studies research examined dermatological scores, such as acne lesion counts and seborrhea (skin oiliness). Data describe patterns related to measured outcomes in dermatological scores. Findings describe patterns observed in the studies, which contributes to the broader evidence landscape regarding antiandrogenic properties.

---

What Is Still Uncertain About Lutéran Research

The overall evidence base is subject to several limitations; evidence quality varies across studies. There is a documented reliance on older trial designs or comparative studies that often did not include a placebo arm for single-agent Lutéran. One major gap is the lack of extensive, high-quality, large-scale randomized controlled trials (RCTs) for single-agent use for many core indications. As mentioned, long-term effects are not fully established, and surveillance for durability of response beyond 12 months is limited.

Common questions about Lutéran (FAQ)

---

Q: What are the ingredients in the Lutéran tablet besides the active drug?

According to the official product information, the Lutéran tablet contains the active substance, Chlormadinone acetate, along with several non-medicinal components known as excipients. These excipients contribute to the tablet's form and stability. The complete and authoritative list of these components is available in the official regulatory documentation.

---

Q: How long does it take for Lutéran to start working or show a noticeable effect?

Pharmacokinetic data indicate the active substance typically reaches its maximum concentration in the bloodstream within a few hours of administration. However, the time required to achieve the full therapeutic effect (the intended change in a medical condition) may vary, often being observed over a prescribed course of treatment across several cycles.

---

Q: Is there a generic version of Lutéran available?

Yes, the active ingredient in Lutéran, Chlormadinone acetate, is available under the brand name Lutéran and may also be marketed under its non-proprietary chemical name as a generic medicinal product in many regions. Official regulatory documents confirm the availability of generics for this active substance.

---

Q: What is the difference between Lutéran (single-agent) and the combination pill (e.g., in a contraceptive)?

Lutéran is a single-agent product, containing only the hormone Chlormadinone acetate, and is typically indicated for specific gynaecological disorders. The combination pill, conversely, contains Chlormadinone acetate plus an estrogen. The combination formulation is typically indicated for contraception (birth control) and utilizes both hormones to support that therapeutic goal.

How to Store and Dispose of Lutéran

Official regulatory guidelines dictate specific storage and disposal requirements for Lutéran (chlormadinone acetate) to ensure product stability and safety.

Storage Requirements

Item	Requirement
Temperature	Store below 25 C (77 F).
Protection	Keep the blisters in the outer carton to protect from light.
Safety	Must be kept out of the sight and reach of children.

Lutéran must be maintained within the specified room temperature range, and the product must remain in its original outer carton to protect the tablets from light and maintain the stability of the active ingredient. The medicine should not be disposed of via wastewater.

Disposal Requirements

Unused or expired Lutéran must be disposed of through an authorized drug take-back program or according to local regulations for pharmaceutical waste. If a take-back program is unavailable, follow regulatory guidance for mixing the medicine with an undesirable substance and sealing it before placing it in the household trash.